Asthma drug to cure horse disease

WA company Stirling Products is working with Danish company Equine HealthCare ApS to develop a ground-breaking inhalation therapy for heaves, a respiratory disease in horses.

The collaboration will make use of Stirling Products' phamaceutical product ST810, which is a more purified form of the asthma drug currently used in human asthma inhalers.

Heaves is the most severe form of chronic obstructive pulmonary disease in horses, with as many as 50% of the 15 million horses in the northern hemisphere suffering from it. The disease is often triggered in horses that spend lots of time in barns and stalls.

Inhalation therapy is recognized by a number of leading specialists as the best form of heaves therapy for horses.

There is also potential for the use of ST810 in treating obesity in animals including domestic pets. ST810 works by redirecting metabolic pathways, so that energy is used to produce protein instead of fat.  

ST810 is neither a steroid nor an antibiotic, and is also able to reduce the fat content of poultry, cattle, sheep and swine by improving their feed efficiency.

About the inventor

Dr Gunnar Aberg is an inventor of over 50 US patents and over 300 international patents, and an author of over 100 publications. He has been an executive in Swedish, Swiss and American pharmaceutical companies and has extensive experience in the areas of pharmaceutical companies and has extensive experience in the areas of pharmaceutical R&D.  Dr Aberg has participated in the successful development of more than a dozen new drugs. 

The potential of ST810 came to Dr Alberg's attention when an Olympic coach asked him about the use of asthma medication by athletes.

Enquiries to Calvin London, Managing Director of Stirling Products Ltd Mobile: 0400 204 616